

Technology Advisory Committee C Interests Register

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Publication Date: 16 December 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Matthew Stevenson	Committee Member	Non-financial professional interest	Professor Matthew Stevenson declared a non-financial professional interest as he is employed by SchARR which was the ERG for risdiplam and he peer reviewed the draft ERG report.	N/A	21.04.2021	N/A	It was agreed that his declaration would not prevent Professor Stevenson from participating in the discussion of the appraisal, however he would not be a voting committee member if a vote was required to determine the outcome of the appraisal.
Mr Michael Chambers	Committee Member	Financial	Mr Chambers has recently been involved in co-ordinating a training programme in real world evidence for Roche Pharmaceuticals (manufacturer of risdiplam), but this has not involved any specific	N/A	26.04.2021	N/A	It was agreed that his declaration would not prevent Mr Chambers from participating in the discussion of the appraisal.

			consideration of Roche products.				
Dr Richard Nicholas	Committee Member	Financial	Dr Nicholas has attended paid advisory boards for Roche and Novartis in an unrelated area.	N/A	26.04.2021	N/A	It was agreed that this declaration would not prevent Dr Nicholas from participating in the discussion of the appraisal.
Dr Prithwiraj Das	Committee Member	Non-financial professional	Dr Das is employed by AstraZeneca UK as the Head of Market Access for Respiratory and Immunology therapies and Vaccines.	N/A	10.05.2021	N/A	It was agreed that this declaration would not prevent Dr Das from participating in the discussion of the appraisal.
Dr Robert Forsyth	Committee Member	Non-financial professional	Dr Forsyth is a paediatric neurologist and, whilst not directly involved in the care of neuromuscular diseases (such as SMA) in children, he has made the diagnosis of SMA in children. He also knows many if not most of the paediatric neurologists caring for SMA in the UK professionally. He was also asked to act as a non-voting	N/A	11.05.2021	N/A	It was agreed that these declarations would not prevent Dr Forsyth from participating in the discussion of the appraisal.

			member/advisor for the nusinersen MAOC.				
Dr Anne-Marie Childs	Clinical expert	Financial & professional	<p>Dr Childs has received professional fees to contribute to advisory boards for Roche, Biogen and Avexis in relation to drug development in SMA.</p> <p>Dr Childs is PI for the observational SMA REACH and iSMAC in Leeds Children's Hospital and is also a medical trustee for SMA UK and a member of the NHSE clinical panel supporting the MAA for nusinersen.</p>	N/A	14.10.2020 11.05.2021	N/A	It was agreed that these declarations would not prevent Dr Childs from providing expert advice to the committee.
Dr Channa Hewamadduma	Clinical expert	Financial & professional	<p>Dr Hewamadduma has received payment from Biogen for delivering a talk on nusinersen treatment in adult patients. He is developing PROMS for adult SMA patients in collaboration with Biogen.</p> <p>Dr Hewamadduma chaired a webinar organised by Biogen on 24 June 2021 on sharing</p>	N/A	16.10.2020 11.05.2021 13.07.2021	N/A	It was agreed that these declarations would not prevent Dr Hewamadduma from providing expert advice to the committee.

			<p>best practice in setting up adult nusinersen services across UK.</p> <p>Dr Hewamadduma has received payment for being on an advisory board of clinical experts for critical analysis of the Roche clinical trial dataset and has taken part in two 'one off' advisory roles to Roche in critical appraisal of evidence for risdiplam</p> <p>Roche organised for Dr Hewamadduma to attend the SMA Europe meeting in February 2020 and also provided him with a travel grant which enabled him to attend the SMA conference.</p>				
--	--	--	---	--	--	--	--